A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer

Lancet

Volumn 347, Issue 9014, 1996, Pages 1523-1527

  Borysiewicz, L K ^a   Fiander, A ^a   Nimako, M ^a   Man, S ^a   Wilkinson, G W G ^a   Westmoreland, D ^a   Evans, A S ^a   Adams, M ^a   Stacey, S N ^b   Boursnell, M E G ^c   Rutherford, E ^c   Hickling, J K ^c   Inglis, S C ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; VACCINIA VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT; WART VIRUS;

EID: 15844365301     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90674-1     Document Type: Article

References (26)

1. Parkin DM, Laara E, Muir CS. Estimates of the world-wide frequency of sixteen major cancers in 1980. Int J Cancer 1980; 41: 184-97.
2. Munoz N, Bosch FX, de Sanjose S, et al. The causal link between human papillomavirus and invasive cervical cancer: a population study based in Columbia and Spain. Int J Cancer 1992; 52: 743-49.
3. Vousden KH. Mechanisms of transformation by HPV. In: Stern PL, Stanley MA, eds. Human papillomaviruses and cervical cancer - biology and immunology. Oxford: Oxford Medical Publications, 1994: 92-115.
4. zur Hausen H. Viruses in human cancers. Science 1991; 254: 1167-73.
5. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type 16 cells. Eur J Immunol 1993; 23: 2242-49.
6. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunisation against human papillomavirus type 16 tumour cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991; 181: 62-69.
7. Chen LP, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumour expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992; 148: 2617-21.
8. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarret WF. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993; 74: 945-53.
9. Rooney CM, Smith CA, Ng CYC, et al. Use of gene modified virus specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation. Lancet 1995; 345: 9-13.
10. Boursnell MEG, Rutherford E, Hickling JK, et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine (in press).
11. Terry G, Ho L, Jenkins D, et al. Definition of human papillomavirus type 16 DNA levels in low and high grade cervical lesions by a simple polymerase chain reaction technique. Arch Virol 1993; 128: 123-33.
12. Fenner F, Henderson DA, Arita L, Jezek Z, Ladnyi LD. Smallpox and its eradication. Geneva: World Health Organization, 1988.
13. Graham S, Green CP, Mason PD, Borysiewicz LK. Human cytotoxic T cell responses to vaccinia virus infection. J Gen Virol 1991; 72: 1183-86.
14. Stacey SN, Bartholomew JS, Ghosh A, Stern PL, Mackett M, Arrand JR. Expression of human papillomavirus type 16 E6 protein by recombinant baculovirus and use for detection of anti-E6 antibodies in human sera. J Gen Virol 1992; 73: 2337-45.
15. Stacey SN, Ghosh A, Bartholomew JS, et al. Expression of human papillomavirus type 16 E7 protein by recombinant baculovirus and use for the detection of antibodies in sera from cervical carcinoma patients. J Med Virol 1993; 40: 14-21.
16. Wilkinson GWG, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res 1992; 20: 2233-39.
17. Borysiewicz LK, Hickling JK, Graham S, et al. Human cytomegalovirus specific cytotoxic T cells recognise the 72kD immediate early protein and glycoprotein B in recombinant vaccinia viruses. J Exp Med 1988; 168: 919-31.
18. Fiander A, Adams M, Evans AS, Bennett AJ, Borysiewicz LK. Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients. Int J Gynaecol Oncol 1995; 5: 438-42.
19. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316: 673-76.
20. Demkowicz WJ, Ennis FA. Vaccinia virus specific CD8+ cytotoxic T lymphocytes in humans. J Virol 1993; 67: 1537-44.
21. Crawford L. Prospects for cancer vaccines. Cancer Surv 1993; 16: 215-29.
22. Aurelian L, Smith CC, Wachsman M, Paoletti E. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunised with vaccinia virus recombinants containing herpex simplex glycoprotein D. Rev Infect Dis 1991; 13: S924-34.
23. Cooney EL, Collier AC, Greenberg PD, et al. Safety and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337: 567-72.
24. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton M, Schlom J. Generation of human cytotoxic T cells for human carcinoembryonic antigen epitopes from patients immunised with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982-90.
25. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumour rejection antigen. Proc Natl Acad Sci USA 1991; 88: 110-14.
26. Tarpey I, Stacey SN, Hickling JK, et al. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif. Immunology 1994; 81: 222-27.